Background: Neoadjuvant chemoradiotherapy is currently the standard strategy for microsatellite stable (MSS) / mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC) patients. This ...

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

“Thus, for upper rectal cancer, the trade-off between using [neoadjuvant radiotherapy] to pursue better oncological outcomes and creating diverting stomas to lower the risk of symptomatic leak ...

CHICAGO — A phase 2 study evaluating dostarlimab in adults with mismatch repair-deficient locally advanced rectal cancer has maintained a 100% clinical complete response rate at a median follow ...

TAMIS is only possible in early-stage disease and most patients present with locally advanced rectal cancer (stage 2). To improve organ preservation and allow these patients to have a better quality ...

The study included 323 patients with locally advanced rectal cancer (cancer that had grown outside the rectum but had not yet spread to other parts of the body) who were treated with either SCRT ...

Upfront chemotherapy and radiotherapy may help reduce the need for surgery in patients with locally advanced rectal surgery, according to recent research. Not only can this treatment method decrease ...

Some of the goals of neoadjuvant therapy can be to reduce the tumor volume making the potential for a complete surgical resection more possible. Neoadjuvant therapy can also allow us to start treating ...